

REVENIO

Revenio Group Corporation's financial reporting and Annual General Meeting in 2023

Revenio Group Corporation, Stock exchange release, October 27, 2022 at 9.15 a.m. (EEST)

Revenio Group Corporation's financial reporting and Annual General Meeting in 2023

Revenio Group Corporation will publish the following financial reports during 2023:

- Financial Statements Bulletin for the year 2022 on Thursday, February 9, 2023
- Annual reporting package 2022 during week 9 in 2023
- Interim report 1-3/2023 on Thursday, April 27, 2023
- Half-year financial report 1-6/2023 on Thursday, August 10, 2023
- Interim report 1-9/2023 on Thursday, October 26, 2023

The financial statements bulletin, half-year report and interim reports will be published at approximately 9.00 am Finnish time on the above dates.

The Annual General Meeting is planned to be held on Thursday, March 23, 2023. The Board of Directors of the company will convene the meeting.

A shareholder, who wishes to include an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 3, 2023. Such requests including the reasoning, or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.

For further information, please contact

Robin Pulkkinen, CFO, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki

Key media

www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

REVENIO

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation's financial reporting and Annual General Meeting in 2023](#)